CellCyte Genetics, the Bothell, WA-based stem cell research company, has shut down. The company said it had a little more than $5,700 in cash at the end of September, according to its quarterly filing with the Securities and Exchange Commission, as reported by The Seattle Times. “We presently do not have sufficient cash to fund our operations, and have curtailed substantially all activities,” the company said in the filing.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
